Cat. #151215
Anti-ErbB4 [HFR1]
Cat. #: 151215
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: ErbB4 (Her4, p180erbB4)
Class: Monoclonal
Application: FACS ; IHC ; IF ; IP ; WB
Reactivity: Human ; Mouse
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Bill Gullick
Institute: Imperial Cancer Research Fund
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-ErbB4 [HFR1]
- Research fields: Cancer;Cell biology;Cell signaling and signal transduction
- Clone: HFR1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human ; Mouse
- Host: Mouse
- Application: FACS ; IHC ; IF ; IP ; WB
- Description: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers.
- Immunogen: Synthetic peptide sequence RSTLQHPDYLQEYST from the cytoplasmic domain of the protein (residues 1249-1264.)
- Isotype: IgG2b
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: ErbB4 (Her4, p180erbB4)
- Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers.
Applications
- Application: FACS ; IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
- Ko et al. 2010. Breast Cancer Res. 12(6):R100. PMID: 21092257.
- Gulati et al. 2010. Diagn Pathol. 5:18. PMID: 20331873.
- Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
- Sundvall et al. 2007. Oncogene. 26(48):6905-14. PMID: 17486069.
- Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
- Carn et al. 2005. Mol Cancer Ther. 4(2):243-55. PMID: 15713896.
- H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
- Srinivasan et al. 1998. J Pathol. 185(3):236-45. PMID: 9771476.
- Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types.
